Please assess the completion status of the following clinical trial:

Trial Title: DP13 - A Phase II Study in Patients With Primary Aldosteronism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients with a guideline-recommended diagnosis of primary aldosteronism~Exclusion Criteria:~Patients with primary aldosteronism and~* hyperkalemia~* prolonged QT intervals~* refusal of special contraception measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 4 mg DP13 daily (Type: EXPERIMENTAL): DP13 for 8 weeks
- 8 mg DP13 daily (Type: EXPERIMENTAL): DP13 for 8 weeks
- 12 mg DP13 daily (Type: EXPERIMENTAL): DP13 for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).